Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

231,451-231,480 of 319,975

filter-aware
06
The slide uses a timeline visual to connect high-level goals with specific 2024 milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left-hand sidebar for board/advisors and a right-hand grid for the leadership team.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
08
The slide uses a standard pharmaceutical pipeline visualization format.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) and their respective treatment challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a case study (Osimertinib) to validate the proposed strategy for ALK/ROS1 targets.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
11
The chart uses a bar-horizontal format to compare sales figures for specific drugs (Alectinib, Crizotinib) against a group of 'Other' TKIs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market Size1 hit
12
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical development parameters.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
13
The slide uses a timeline-based framework to map treatment lines (1L, 2L, 3L+) against clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a matrix-style comparison to highlight the superior coverage of NVL-655 compared to 1st, 2nd, and 3rd generation inhibitors.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
The slide uses two distinct chart types (bar and scatter) to demonstrate pharmacological advantages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed patient enrollment breakdown by dose cohort and trial phase.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The chart shows NVL-655 pharmacokinetics across five dose cohorts, highlighting that the 150mg dose maintains levels above efficacy thresholds for various ALK mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Includes a table detailing patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
Uses a timeline-based framework to contrast current treatment standards with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a visual comparison matrix to highlight the therapeutic advantages of Zidesamtinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate competitive superiority in potency, CNS penetration, and selectivity.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (25mg to 125mg QD) for the ARROS-1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes a waterfall plot and a summary table of best responses.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data for Zidesamtinib (NVL-520) in ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data from ARROS-1 Phase 1 trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit